Announcement of board meeting approved the consolidated financial statements for the second quarter of 2022
· Issued by SciVision Biotech Inc.
Close
Today's Information
Provided by: SciVision Biotech Inc.
SEQ_NO
1
Date of announcement
2022/08/03
Time of announcement
15:59:14
Subject
Announcement of board meeting approved the
consolidated financial statements for the second quarter
of 2022
Date of events
2022/08/03
To which item it meets
paragraph 31
Statement
1.Date of submission to the board of directors or approval by the board of
directors:2022/08/03
2.Date of approval by the audit committee:2022/08/03
3.Start and end dates of financial reports or annual self-assessed financial
information of the reporting period (XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):232,578
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):145,728
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):40,731
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):79,865
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):66,626
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):66,626
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):1.01
11.Total assets end of the period (thousand NTD):2,015,862
12.Total liabilities end of the period
(thousand NTD):593,162
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,422,700
14.Any other matters that need to be specified:None
